Back to Search
Start Over
[Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
- Source :
-
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2019 Sep 23; Vol. 41 (9), pp. 641-647. - Publication Year :
- 2019
-
Abstract
- Over the past decades, although the clinical efficacy of advanced head and neck squamous cell carcinoma (HNSCC) has been moderately improved by the combination of cetuximab and chemotherapy, no remarkable treatment has emerged. The prognosis of HNSCC is still unsatisfied. With the deeper exploration of tumor immunological therapy, immunocheckpoint inhibitors such as monoclonal antibodies targeting on programmed cell death protein 1 (PD-1)/ cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have shown appreciable anti-tumor effect on cancers such as melanoma and non-small cell lung cancer. Some successful clinical studies on HNSCC have also been reported, which provide a new opportunity for the improvement of HNSCC prognosis.Here we systemically review the progress of checkpoint inhibitors and its combination therapy in HNSCC, some immunotherapy efficacy-related biomarkers are also discussed.
- Subjects :
- CTLA-4 Antigen antagonists & inhibitors
Head and Neck Neoplasms immunology
Head and Neck Neoplasms pathology
Humans
Programmed Cell Death 1 Receptor immunology
Squamous Cell Carcinoma of Head and Neck immunology
Squamous Cell Carcinoma of Head and Neck pathology
Antibodies, Monoclonal therapeutic use
Antineoplastic Agents, Immunological therapeutic use
Head and Neck Neoplasms therapy
Immunotherapy methods
Squamous Cell Carcinoma of Head and Neck therapy
Subjects
Details
- Language :
- Chinese
- ISSN :
- 0253-3766
- Volume :
- 41
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Zhonghua zhong liu za zhi [Chinese journal of oncology]
- Publication Type :
- Academic Journal
- Accession number :
- 31550852
- Full Text :
- https://doi.org/10.3760/cma.j.issn.0253-3766.2019.09.001